Devalingam Mahalingam

7.1k total citations · 1 hit paper
186 papers, 5.4k citations indexed

About

Devalingam Mahalingam is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Devalingam Mahalingam has authored 186 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Oncology, 66 papers in Molecular Biology and 45 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Devalingam Mahalingam's work include Pancreatic and Hepatic Oncology Research (23 papers), Colorectal Cancer Treatments and Studies (23 papers) and Hepatocellular Carcinoma Treatment and Prognosis (19 papers). Devalingam Mahalingam is often cited by papers focused on Pancreatic and Hepatic Oncology Research (23 papers), Colorectal Cancer Treatments and Studies (23 papers) and Hepatocellular Carcinoma Treatment and Prognosis (19 papers). Devalingam Mahalingam collaborates with scholars based in United States, Spain and Netherlands. Devalingam Mahalingam's co-authors include Francis J. Giles, Jennifer S. Carew, Steffan T. Nawrocki, Ronan Swords, Massimo Cristofanilli, Kevin R. Kelly, Sukeshi Patel Arora, Elena Vagia, John Sarantopoulos and Alain C. Mita and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Devalingam Mahalingam

177 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Landscape of Targeted Therapies in TNBC

2020 305 citations Devalingam Mahalingam et al. profile →

Peers

Countries citing papers authored by Devalingam Mahalingam

Since Specialization

Citations

This map shows the geographic impact of Devalingam Mahalingam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Devalingam Mahalingam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Devalingam Mahalingam more than expected).

Fields of papers citing papers by Devalingam Mahalingam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Devalingam Mahalingam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Devalingam Mahalingam. The network helps show where Devalingam Mahalingam may publish in the future.

Co-authorship network of co-authors of Devalingam Mahalingam

This figure shows the co-authorship network connecting the top 25 collaborators of Devalingam Mahalingam. A scholar is included among the top collaborators of Devalingam Mahalingam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Devalingam Mahalingam. Devalingam Mahalingam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Delta Radiomics and Tumor Size: A New Predictive Radiomics Model for Chemotherapy Response in Liver Metastases from Breast and Colorectal Cancer 2025 ·Tomography ·Nicolò Gennaro, (unknown), Amir A. Borhani, Linda C. Kelahan, Hatice Savas, Ryan Avery, (unknown), (unknown), Chase Krumpelman, Vahid Yaghmai, Young Kwang Chae, Jochen H. Lorch, Devalingam Mahalingam, Mary F. Mulcahy, Al B. Benson, Ulaş Bağcı, Yury Velichko	0
2	DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B 2025 ·Nature Communications ·Keun Wook Lee, Devalingam Mahalingam, Byoung Yong Shim, In-Ho Kim, Do‐Youn Oh, Hope E. Uronis, Sun Jin Sym, Mohamad Bassam Sonbol, Khaldoun Almhanna, Mohamedtaki Abdulaziz Tejani, (unknown), Michael H. Kagey, (unknown), (unknown), Cynthia A. Sirard, (unknown), Jaffer A. Ajani, Samuel J. Klempner	0
3	Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial 2024 ·Clinical Lung Cancer ·Jonathan W. Goldman, (unknown), Christophe Dooms, Komal Jhaveri, Maria J. de Miguel, Sarina A. Piha‐Paul, Nisha Unni, Aviad Zick, Amit Mahipal, Jennifer M. Suga, Charles Naltet, (unknown), John Crown, Judith D. Bebchuk, Lisa D. Eli, (unknown), Devalingam Mahalingam	1
4	Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04). 2024 ·Journal of Clinical Oncology ·Vaibhav Sahai, Kent A. Griffith, David B. Zhen, Dustin A. Deming, Rachna T. Shroff, David Hsieh, Devalingam Mahalingam, Oxana Crysler, Angela Alistar, David L. Bajor, Thomas Enzler, Mark M. Zalupski	2
5	A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009). 2024 ·Journal of Clinical Oncology ·Hao Xie, Anthony B. El-Khoueiry, Angela Alistar, Hani M. Babiker, Devalingam Mahalingam, Minal Barve, Joohyuk Sohn, Mitesh J. Borad, Jae-Cheol Lee, (unknown), (unknown), Jin‐Ho Choi, Jeongjun Kim, Donghoon Yu, Seungjoo Lee, (unknown), Stefan Proniuk, Jaeseung Kim, Kiyean Nam	2
6	A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2 - Altered Advanced Solid Tumor Malignancies (NCI 10170) 2024 ·Cancer Research Communications ·(unknown), W. Kimryn Rathmell, Geoffrey I. Shapiro, Naoko Takebe, Jordi Rodón, Devalingam Mahalingam, Nikolaos A. Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A. Boerner, (unknown), Gregor Krings, Timothy F. Burns, Emily K. Bergsland, Pamela N. Münster, Alan Ashworth, Patricia LoRusso, Rahul Aggarwal	6
7	Safety and feasibility of establishing an adjuvant hepatic artery infusion program 2023 ·HPB ·(unknown), (unknown), Amir A. Borhani, Robert J. Lewandowski, Yury Velichko, Mary F. Mulcahy, Devalingam Mahalingam, Jennifer Law, (unknown), Rajesh N. Keswani, Vitaliy Poylin, David J. Bentrem, Ryan P. Merkow	5
8	Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer 2020 ·Clinical Cancer Research ·Lipika Goyal, Cynthia A. Sirard, Michael Schrag, Michael H. Kagey, Jennifer R. Eads, Stacey Stein, Anthony B. El-Khoueiry, Gulam A. Manji, Thomas A. Abrams, Alok A. Khorana, Rebecca A. Miksad, Devalingam Mahalingam, Andrew X. Zhu, Dan G. Duda	46
9	Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours 2020 ·British Journal of Clinical Pharmacology ·Devalingam Mahalingam, Manish R. Patel, Jasgit C. Sachdev, Lowell L. Hart, Niels Halama, Ramesh K. Ramanathan, John Sarantopoulos, Dirk Völkel, (unknown), Floris A. de Jong, Apostolia M. Tsimberidou	49
10	Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity 2019 ·Clinical Cancer Research ·Devalingam Mahalingam, Judy S. Wang, Erika Hamilton, John Sarantopoulos, John Nemunaitis, (unknown), Laura Carter, Xiao Hu, Marshall T. Schreeder, H. Jeffrey Wilkins	47
11	Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study 2019 ·Clinical Cancer Research ·Devalingam Mahalingam, Grey Wilkinson, Kevin H. Eng, Paul Fields, Patrick Raber, Jennifer L. Moseley, (unknown), Matt Coffey, Gerard J. Nuovo, Paweł Kaliński, Bin Zhang, Sukeshi Patel Arora, Christos Fountzilas	142
12	Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx ^® ): a placebo-controlled randomised phase II study (PLIANT) 2017 ·Acta Oncologica ·Bengt Glimelius, Nebojša Manojlović, Per Pfeiffer, Baadur Mosidze, G. Kurteva, (unknown), Devalingam Mahalingam, Peter Buhl Jensen, Jan Kowalski, (unknown), (unknown), (unknown)	63
13	Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes 2016 ·Cancer Prevention Research ·Chen-Pin Wang, Donna M. Lehman, (unknown), John G. Kuhn, Devalingam Mahalingam, Steven Weitman, Carlos Lorenzo, John R. Downs, Elizabeth A. Stuart, Javier Hernández, Ian M. Thompson, Amelie G. Ramírez	20
14	CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients 2015 ·Clinical Cancer Research ·Fabian Birzele, Edgar Voß, Adam Nopora, Konrad Honold, Florian Heil, (unknown), Henk M.W. Verheul, Christophe Le Tourneau, Jean‐Pierre Delord, Carla van Herpen, Devalingam Mahalingam, Andrew L. Coveler, Valérie Méresse, Stefan Weigand, Valeria Runza, Michael A. Cannarile	45
15	Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors 2015 ·Clinical Cancer Research ·John Sarantopoulos, Geoffrey I. Shapiro, Roger B. Cohen, Jeffrey W. Clark, John Kauh, Glen J. Weiss, James M. Cleary, Devalingam Mahalingam, Michael D. Pickard, Hélène M. Faessel, Allison Berger, Kristine Burke, George Mulligan, Bruce J. Dezube, R. Donald Harvey	139
16	Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer 2015 ·Oncotarget ·(unknown), Tai Qin, (unknown), James E. Schmitz, (unknown), Roberto J. Fajardo, Devalingam Mahalingam, Xiao‐Dong Chen, Xueqiong Zhu, Lu‐Zhe Sun	50
17	A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors 2014 ·Clinical Cancer Research ·Jordi Rodón, Hussein Tawbi, Anne Thomas, Ronald G. Stoller, Christian P. Turtschi, José Baselga, John Sarantopoulos, Devalingam Mahalingam, Yaping Shou, Melissa A. Moles, Lin Yang, Camille Granvil, Eunju Hurh, Kristine Rose, Dereck D. Amakye, Reinhard Dummer, Alain C. Mita	187
18	Inhibition of Hedgehog and Androgen Receptor Signaling Pathways Produced Synergistic Suppression of Castration-Resistant Prostate Cancer Progression 2013 ·Molecular Cancer Research ·Pramod S. Gowda, (unknown), (unknown), Abhik Bandyopadhyay, Sitai Liang, (unknown), Devalingam Mahalingam, Lu‐Zhe Sun	18
19	Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors 2012 ·Clinical Cancer Research ·Lee S. Rosen, Igor Puzanov, Gregory Friberg, Emily Chan, Yuying C. Hwang, Hongjie Deng, Jill Gilbert, Devalingam Mahalingam, Ian McCaffery, (unknown), Alain C. Mita, Monica Mita, Marilyn Mulay, (unknown), Min Zhu, John Sarantopoulos	30
20	Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model 2009 ·Clinical Cancer Research ·Evelien W. Duiker, Elisabeth G.E. de Vries, Devalingam Mahalingam, Gert Jan Meersma, (unknown), Harry Hollema, (unknown), (unknown), Robbert H. Cool, Wim J. Quax, Afshin Samali, Ate G.J. van der Zee, Steven de Jong	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact